Interferon beta is widely used for the treatment of relapsing and remitting multiple sclerosis. Renal side effects including nephrotic syndrome have been increasingly described with interferon beta treatment. We describe an illustrative case of a patient who developed severe nephrotic syndrome due to minimal change disease in association with interferon beta therapy and showed partial remission following cessation of interferon beta and treatment with corticosteroids.
Introduction
Interferon beta (IFN-β) is well established as a standard treatment for relapsing remitting multiple sclerosis (RRMS). The drug is usually well tolerated, but constitutional side effects and autoimmune adverse effects have been reported. Proteinuria has also been reported but is a rare side effect. We report a case of nephrotic syndrome following interferon beta-1a (IFN-β-1a) therapy, for RRMS, and partial remission following drug withdrawal and steroid therapy.
Case
A 44-year-old female with a 4-year history of RRMS was admitted for evaluation of pedal oedema of 3-month duration. She had spasticity involving both lower limbs and required intermittent self-catheterization for bladder spasticity. She fulfilled the diagnostic criteria for RRMS, defined by more than two attacks within 18 months. Subcutaneous IFN-β-1a treatment of 44 mcg thrice weekly was commenced 20 months prior to this admission. Twelve months previously, she also received a course of methylprednisolone for severe disease exacerbation. She had a 6-month history of type 2 diabetes mellitus with no micro vascular complications and was on metformin and gliclazide.
There was no past or family history of renal disease. Her blood pressure was 140/90 mmHg. Initial investigations showed creatinine 82 μmol/L, HbA1C 7.0%, serum albumin 24 g/L, total cholesterol 4.9 mmol/L and triglycerides 6.5 mmol/L. Urine examination revealed 10-100 erythrocytes/high power field. No dysmorphic red cells or casts were found. Proteinuria was quantified at 42 g/24 h. ENA, ANA, ANCA and ds-DNA were negative and C3 and C4 levels were normal. Electrophoresis and immunoelectrophoresis of urine and serum were negative for paraprotein. A renal biopsy was normal on light microscopy. Immunofluorescence for IgG, IgA, IgM, C1q, C3, kappa and lambda light chains was negative. Electron microscopy revealed the extensive foot process effacement characteristic of minimal change disease (MCD) (Figures 1 and 2 ). IFN-β-1a was withdrawn. Her proteinuria decreased from 42 to 14 g/day after 2 weeks. She was treated with intravenous methyl prednisolone 1 g for three consecutive days, followed by oral prednisone 1 mg/kg/day along with ramipril 10 mg/day and atorvastatin 80 mg/day. Proteinuria decreased to <1 g/24 h at 3 months. Steroids were withdrawn and when last seen, 7 months after initial presentation, proteinuria was maintained at <1 g/24 h. Pedal oedema completely resolved, blood pressure was 120/80 mmHg and renal function remained normal.
Discussion
IFNs are widely used for the treatment of various malignancies, hepatitis C and multiple sclerosis. INF-β is postulated to act in multiple sclerosis by inhibiting proliferation and activation of T cells. INF-β also inhibits T-cell migration across the blood-brain barrier [1] . Although considered safe, interferon therapy is associated with side effects, especially flu-like symptoms, fatigue and anorexia. Renal side effects are uncommon, mild and are more frequently described with INF-α. Rare severe manifestations include acute renal failure secondary to acute tubular necrosis or acute interstitial nephritis [2] , haemolytic uraemic syndrome [3] , focal segmental glomerulosclerosis (FSGS) [4] and MCD. Induction of autoimmunity and autoantibody production resulting in glomerular immune deposition is thought to be the mechanism of renal side effects of INF.
The incidence of transient proteinuria during IFN-β therapy is ∼20%. To our knowledge, only four cases of nephrotic syndrome associated with IFN-β treatment have been previously reported. Gotsman et al. [5] described a 52-year-old female who developed nephrotic syndrome 4 months after IFN-β treatment for multiple sclerosis. Proteinuria was found to be 4.6 g/24 h and a biopsy revealed FSGS. Proteinuria resolved with withdrawal of INF alone. Nephrotic syndrome was described in a 39-yearold man with RRMS 22 months after commencing IFN-β.
The biopsy showed MCD with proteinuria of 6.7 g/24 h. Nephrotic syndrome resolved in 6 weeks with oral prednisolone [6] . The patient relapsed at 8 months, and remission was achieved again with steroids and azathioprine. The third case is a 28-year-old male with proteinuria of 36 g/ 24 h, occurring 22 months after IFN-β therapy. Proteinuria persisted after withdrawal of INF. There was a partial response to methyl prednisolone and a complete response with the addition of cyclosporine and mycophenolate mofetil [7] . MCD has been described in another patient with multiple sclerosis, occurring 21 months after treatment with IFN-β-1b. This patient required a course of corticosteroids, as the nephrotic state persisted after drug cessation alone. Interestingly, she was re-treated successfully with IFN-β without recurrence of nephrosis [8] .
The mechanism for the development of nephrotic syndrome associated with IFN-β is not clear. The immune modulatory effects of IFN may play a role. It has also been proposed that IFN may be directly nephrotoxic. It has been well documented that patients on IFN develop neutralizing antibodies in the serum. Antigen-antibody complex formation and subsequent deposition in the glomerular basement membrane may also play a role in the development of nephrotic syndrome [9] . However, the failure to demonstrate immune deposits on immunofluorescence in our patient argues against this theory. It has also been postulated that the anionic charge of the IFN may neutralize the cationic charge of the glomerular basement membrane altering its permeability [9] .
Renal complications have not been ascribed directly to multiple sclerosis. There exists one case report describing a case of membranous glomerulonephritis and thrombocytopaenia in a patient with progressive multiple sclerosis [10] . However, this is likely to be a de novo, sporadic renal condition unrelated to multiple sclerosis. The temporal association with IFN drug therapy in our patient suggests that the severe nephrotic syndrome was most likely due to drug therapy rather than a direct complication of multiple sclerosis.
In conclusion, our case illustrates an uncommon renal complication of IFN-β therapy, and we alert others to be mindful that long-term treatment with IFN-β may cause proteinuria and nephrotic syndrome. Periodic urine analysis for proteinuria should be performed in patients receiving long-term IFN-β therapy for RRMS. Heavy or persisting proteinuria and nephrotic syndrome may warrant a renal biopsy to exclude an underlying primary glomerular disease.
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